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Background: Urokinase-type plasminogen activator
(u-PA) promotes fibrinolysis by catalyzing the conversion
of plasminogen to the active protease plasmin via the
cleavage of a peptide bond. When localized to the exter-
nal cell surface it contributes to tissue remodelling and
cellular migration; inhibition of its activity impedes the
spread of cancer. u-PA has three domains: an N-terminal
receptor-binding growth factor domain, a central kringle
domain and a C-terminal catalytic protease domain. The
biological roles of the fibrinolytic enzymes render them
therapeutic targets, however, until now no structure of
the protease domain has been available. Solution of the
structure of the u-PA serine protease was undertaken to
provide such data.
Results: The crystal structure of the catalytic domain of
recombinant, non-glycosylated human u-PA, complexed
with the inhibitor Glu-Gly-Arg chloromethyl ketone
(EGRcmk), has been determined at a nominal resolution
of 2.5 A and refined to a crystallographic R-factor of
22.4% on all data (20.4% on data >3cr). The enzyme has
the expected topology of a trypsin-like serine protease.
Conclusions: The enzyme has an S1 specificity pocket
similar to that of trypsin, a restricted, less accessible,
hydrophobic S2 pocket and a solvent-accessible S3 pocket
which is capable of accommodating a wide range of
residues. The EGRcmk inhibitor binds covalently at the
active site to form a tetrahedral hemiketal structure.
Although the overall structure is similar to that of homol-
ogous serine proteases, at six positions insertions of extra
residues in loop regions create unique surface areas. One
of these loop regions is highly mobile despite being
anchored by the disulphide bridge which is characteristic
of a small subset of serine proteases namely tissuetype plas-
minogen activator, Factor XII and Complement Factor I.
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Introduction
Human urokinase-type plasminogen activator (u-PA; EC
3.4.21.73) is a 54 kDa (411 residues) multidomain glyco-
protein, glycosylated at Asn302, that converts the zymo-
gen plasminogen to its active form plasmin by hydrolysis
of its Arg561-Val562 peptide bond. Together with tissue-
type plasminogen activator (t-PA), u-PA is one of the two
major endogenous plasminogen activators. Two forms of
u-PA exist: single-chain (sc) u-PA, which possesses a very
low amidolytic activity and two-chain (tc) u-PA, which is
the highly active form generated in a positive-feedback
mechanism involving plasmin-mediated proteolysis of the
sc-u-PA Lysl58-Ile159 peptide bond [1,2] yielding
chains A (residues 1-158) and B (residues 159-411).
Subsequent to proteolytic activation of sc-u-PA, the
N terminus (A chain) of tc-u-PA, which contains a
sequence homologous to that of human epidermal
growth factor (EGF) and one homologous to those of
kringle domains, remains covalently linked to the C-ter-
minal (B chain) serine protease domain by a single
disulphide bridge (Cysl48-Cys279) [3,4]. Further incu-
bation of tc-u-PA, alone or with plasmin, results in
release of the two N-terminal domains from the C-ter-
minal domain due to cleavage of the Lysl35-Lysl36
peptide bond. The catalytic domain of the B chain
(residues 159-411), joined by a disulphide bridge to a
severely truncated A-chain fragment (residues 136-158)
[4] has been termed low molecular weight u-PA (LMW
u-PA, molecular weight -33 kDa), and it is the structure
of this two-chain molecule that we discuss.
Localization of u-PA to the cell surface is achieved via a
specific u-PA receptor (u-PAR) which is believed to
interact with the EGF-like domain of u-PA [5]. u-PA
may then activate plasminogen within this receptor
complex. This leads to plasmin-mediated hydrolysis of
fibrin and other extracellular matrix components, such
as fibronectin and laminin, as well as to the activation of
plasminogen activators, latent growth factors and matrix
metalloproteases [4,6]. Extravascular plasminogen acti-
vation, leading to tissue remodelling and cellular
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migration, is thought to be mediated by u-PA [7,8],
whereas intravascular activation, which is the initiating
step in the dissolution of blood clots, is thought to be
predominately mediated by (t-PA). Such a partition of
roles is, however, not absolute [9]. High levels of u-PA,
bound to u-PAR, have been shown to exist at the
invasion fronts of tumours. This suggests several possible
targets for anti-metastatic therapy, including antagonists
of the interaction between u-PA and u-PAR, and
inhibitors of u-PA activity directed to its active site. In
contrast to trypsin, which is a relatively non-specific
protease, u-PA has only a small number of molecular
substrates. In addition to plasminogen, these include
fibronectin, u-PAR and hepatocyte growth factor/scat-
ter factor [6]. Biological inhibition of u-PA's proteolytic
action is mediated specifically by plasminogen activator
inhibitor types 1 and 2 and the protease nexin-1 [10].
The tertiary structure of full length sc-u-PA or tc-u-PA
has not yet been determined, although crystals of intact
tc-u-PA have been reported [11]. Similarly, the structures
of t-PA and plasmin are unknown. The lack of viable
crystals for structure determination of intact u-PA is
probably due to the high degree of structural and motile
independence of the three domains [12-16]. NMR
structures are available for the isolated kringle domain
[17] and for the N-terminal fragment (ATF) [18], which
comprises the kringle domain linked to the EGF-like
domain. The crystal structure of LMW u-PA reported
here completes the structure determination of the three
u-PA domains. An overall representation of the u-PA
molecule is shown schematically in Figure 1. The LMW
u-PA structure represents the first determination of a
serine protease domain structure from the enzymes of the
fibrinolytic system, and complements recent reports of
structural determination of serine proteases from the
blood coagulation (thrombin [19] and Factor X [20]) and
complement (Factor D [21]) systems.
Results and discussion
Structure determination
Crystals of recombinant, non-glycosylated, human
LMW u-PA (residues 159-411 of full-length u-PA)
were grown from solutions containing both PEG 8000
and lithium sulphate over periods ranging from 24 h to
4 weeks. The crystals were of dimensions
0.25 x0.25x0.15mm3 and had a rhombohedral mor-
phology. Initial data collection on an 'in-house' X-ray
source demonstrated that the crystals belonged to space
group R3 with unit cell dimensions of a=b=176.7 A,
c=54.4 A. Assuming two molecules in the asymmetric
unit, the solvent content of the cell was estimated at
60%. Diffraction studies undertaken at a synchrotron
source allowed the collection of diffraction data extend-
ing to 2.5 A resolution. The data set was 60% complete
to 2.5 A (on observations >3u), with an overall
R-merge of 11.1% (Table 1).
Initial attempts at molecular replacement within the
X-PLOR package [22], using the high-resolution struc-
ture of oa-chymotrypsin [23] and other known trypsin-
like serine protease structures, failed. Subsequent searches
conducted using only those atoms in the core of these
models (those within 15 A of the centre of mass) pro-
duced clear solutions for the orientations and positions of
both molecules within the asymmetric unit. The wealth
of structural information available for members of the
serine protease family allowed multiple LMW u-PA
models to be constructed and refined. Electron-density
maps, calculated from these models, were then averaged
to reduce model bias.
Fig. 1. Schematic representation of the three structural domains
of u-PA: epidermal growth factor-like, kringle and serine protease
domains.
The current model, with bulk solvent correction, has
been refined to a crystallographic R-factor of 22.4% on
all data (20.4% for those reflections where F>3(). Data
were weak and the data set was incomplete in the higher
resolution shells, overall completeness dropping from
94% at 3.2 A to 70% at 2.5 A on all observations and
Table 1. X-ray data.
Data set X d min Unique No. of Completeness Rmerge*
(A) (A) reflections measurements (%) (%)
In-house 1.542 3.1 10153 35629 94.9 10.0
Photon
Factory 0.97 2.5 11394 18911 50.8 6.2
All 15684 54540 67.8 11.1
rge i I (lh-hi) X100
*Rmerge=~ 'hi
,Phihi
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from 88% at 3.2 A to 60% at 2.5 A for observations
>3cr. In all, 255 of the 275 residues present in the crys-
tallized fragment have been fitted to the electron density.
Of the 20 not fitted, because of a lack of definition
within the electron density, 12 (residues 136-147) are
contained in the N terminus, which is the linker region
between the kringle and serine protease domains in full-
length u-PA, three (residues 156-158) are at the C ter-
minus of the A chain and the remaining five (residues
407-411) are found at the C terminus of the B chain.
The model has good geometry. The root mean square
(rms) deviations from bond length and angle ideality are
0.013 A and 2.00 respectively, and all non-glycine
residues are in the allowed regions of the Ramachandran
plot [24], although the 0,q angles of Tyr284, Trp347 and
Ala381 are in less favoured regions. The two non-crystal-
lographic copies contain no significant differences (Cot
atom rms deviation of 0.52 A). For the 35% of atoms
that were non-crystallographically restrained throughout
the refinement, the rms deviation between subunits is
0.35 A. The temperature factors have an rms deviation
between bonded backbone atoms of 5.7 A2 and average
main-chain and side-chain values of 37.8 A2 and
44.0 A2, respectively.
Overall structure and nomenclature
The structure of LMW u-PA exhibits the typical topol-
ogy of a trypsin-like serine protease and consists of a
spherical protein, of approximately 25 A in radius,
folded into two subdomains of antiparallel -barrel
structure. The subdomains are related by a pseudo-
twofold axis (Fig. 2). By convention, numbering of
residues from within serine protease B-chain sub-
domains is based on their structural equivalents in
a-chymotrypsin: this convention is used throughout the
rest of the paper (Fig. 3). The active site, containing the
catalytic triad of His57, AsplO02 and Ser195 residues, is
contained at the interface between the two subdomains.
Structural alignment, using the SHP program [25],
showed that 220 of the 239 residues contained in the
LMW u-PA B chain have topological equivalents in
ot-chymotrypsin. The 19 non-equivalent residues (i.e.
insertions in LMW u-PA compared with ax-chy-
motrypsin) are assigned the number of the preceding
Fig. 2. Overall structure of LMW u-PA. (a)
Stereo diagram of Cc trace. (b) Secondary
structural elements of LMW u-PA high-
lighting the additional disulphide bond
Cys50O-Cysl 111 (yellow) and the glycosyla-
tion site at Asn145 (orange sphere) in the
native molecule. The glycosylation site is
situated in a position which is very
unlikely to interfere with regions of sub-
strate interaction. Figure produced by
MOLSCRIPT [52] (as modified by Robert
Esnouf) and RASTER3D [53].
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residues following Cysl, five (residues 2-6) were unam-
biguously fitted to the electron density and a further two
(residues 7 and 8) were modelled tentatively in weak
density. The direction of the chain diverges at residue 4
from that observed in ot-chymotrypsin, projecting away
from the B chain of the molecule into the solvent. This is
consistent with the A-chain conformations observed in
thrombin and Factor X; there seems to be no conserved
structure for this C-terminal region of the A chain in
the trypsin-like serine proteases.
Fig. 3. Nomenclature for numbering the residues of LMW u-PA.
The first two rows show a structural alignment between chy-
motrypsin and LMW u-PA: structurally variable loops are shown
in red, conserved residues in yellow. Residues involved in LMW
u-PA's additional disulphide bridge are highlighted in blue; those
residues not fitted to the electron density map are in green. The
sequence of tissue-type plasminogen activator t-PA serine pro-
tease is shown in the third row, based upon a sequence alignment
with LMW u-PA. It shows 46% sequence identity to LMW u-PA.
topological equivalent supplemented by letters in alpha-
betical order (e.g. 37A, 37B, 37C etc.; see Fig. 3). The
residues of the A chain are numbered sequentially from
the conserved Cysl (Cysl48 in full-length u-PA) whilst
those of the peptide inhibitor are assigned 11-31.
According to convention, those residues on the acyl-
group side of the scissile bond of substrates are num-
bered P1, P2, P3, etc. towards the N terminus while
those on the leaving-group side are numbered Pi', P2',
P3', etc. towards the C terminus. The corresponding
binding sites on the enzyme for these residues are
denoted S1, S2, S3 and Si', S2', S3'. According to this
convention residue 1I corresponds to P3 and 31 to P1.
The A chain
The A chain of the molecule is composed of 23 residues
connected to the B chain via a disulphide bridge
(Cysl-Cysl36). The 12 residues before Cysl, which in
the full-length protein form the linker region between
the kringle and the serine protease domains, are dis-
ordered as no interpretable electron density was observed
for them. This is consistent with the linker region being
unstructured in intact u-PA, and indeed considerable
flexibility between the kringle and the protease domains
has been observed in NMR studies [14]. Of the ten
The B chain
Each of the two subdomains in the B chain contains six
3-strands folded in an antiparallel manner and connected
by turn or helical regions. Of the three helical regions,
the N-terminal subdomain contains one 310-helix
(residues 55-59), whilst the C-terminal subdomain con-
tains one ao/310 -helix (residues 164-170) and one
oc-helix (residues 234-243). These secondary structure
features are conserved among serine proteases and thus
have been designated structurally conserved regions
(SCRs). In contrast, the loops connecting these con-
served elements differ across the family, frequently con-
taining insertions, and are termed variable regions (VRs)
[26,27]. We will consider six VRs found in the B chain
of LMW u-PA (Fig. 2b) which have no structural coun-
terparts in either the digestive (chymotrypsin, trypsin,
and elastase) or coagulation cascade (thrombin and Factor
X) serine proteases.
The first VR, (VR1; (Fig. 4a) is a four-residue insertion
(Arg37A-Gly37B-Gly37C-Ser37D) in the loop
between the first and second 13-strands. It forms a flexi-
ble loop which extends into the solvent. Gly37B adopts
a conformation that would be unfavourable for other
residue types, whereas Gly37C is incorporated in a type
I turn. The insertion follows a stretch of positively
charged residues (Arg35-Arg36-His37) which, with
Arg37A, form a positively charged surface patch (Fig. 5).
Mutagenesis studies [28] have indicated that this patch
may function, in part, as a binding site for plasminogen
activator inhibitors. The second VR, VR2, a three-
residue insertion (Asp60A-Tyr60B-Pro60C) in the loop
between the second and third 3-strands, follows the
conserved disulphide bridge (Cys42-Cys58). Tyr60B is
5 A from Arg37A of VR1 and thus the two insertions,
adjacent in three dimensions, provide a unique surface
region. VR3 is at the active-site cleft of the enzyme
(Fig. 4b). A two-residue hydrophobic insertion
(Thr97A-Leu97B) extends the loop between the fourth
and fifth -strands to form a lip to the binding cleft. A
hydrophobic face is created in the substrate-binding
pocket by Leu97B and Ala98.
VR4 (Fig. 4c), a four-residue insertion (LysIlOA-
Glul lOB-Glyl lOC-Arg110lOD) immediately precedes a
disulphide bridge (Cys50-Cysl 11) present only in a small
subset of serine protease sequences namely u-PA, t-PA,
Factor XII and human complement Factor I. Davidow
etal. [29] found that the u-PA variant Cyslll --Tyr
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Fig. 4. Stereo diagrams [52] illustrating
the local conformation of significant
variable regions (VRs) superposed on
the ca-chymotrypsin structure [23]. (a-c)
VR1, VR3 and VR4, respectively. The
atoms of u-PA are shown in standard
atom colours, those of cL-chymotrypsin
in orange, while the carbon atoms of
the EGRcmk inhibitor are in green [part
(b) only].
possessed only 7% of the activator activity of wild type u-
PA. (Other mutations performed by Davidow and co-
workers are shown in Fig. 6). VR4, which extends into
the solvent and forms a charged surface loop, is highly
mobile (with a mean Cot B-factor of 89 A2 ). Thus, it
seems likely that the role of the additional disulphide
bond is to promote the stabilization of this inherently
mobile region. VR5 (Prol70A-His170B) provides an
alternative way of forming the turn between the short
310-helical stretch (residues 168-170) and the ninth 3-
strand. The inserted proline acts as a 'helix breaker' and,
with the histidine, forms a type I turn. The sixth and final
VR, VR6, again incorporates a proline at a turn
(Prol85A-Gln185B). This insertion precedes Asp189,
the acidic residue in the substrate-binding pocket which
confers arginine specificity, yet the insertion does not dis-
tort the pocket. Thus, Pro185A provides an alternative
way of attaining viable active-site geometry.
Activation
The N-terminal residue of the B chain, Ile16, is struc-
turally equivalent to corresponding residues of other
active trypsin-like serine protease structures. A salt
bridge, between the o-ammonium group of Ile16 and
the side-chain carboxylate of Asp194, is also a feature
common to these structures. By analogy, this suggests
that the structural alterations which lead to zymogen
activation in chymotrypsinogen and trypsinogen [30,31]
also occur in the proteolytic generation of fully active
tc-u-PA. In these pathways, cleavage of the Argl5-Ile16
peptide bond results in the stabilization of the
Ile16-Aspl94 salt bridge, and generates the oxyanion
hole [32]. Madison et al. [33] have proposed that the
presence of a 'zymogen triad' of Ser32-His40-Asp194 in
serine protease single-chain zymogens antagonizes
oxyanion hole formation, thereby resulting in their high
level of zymogenicity (defined as the ratio of activities of
686 Structure 1995, Vol 3 No 7
Fig. 5. GRASP [35] representations of LMW u-PA. Regions of
negative charge are shown in red, those of positive charge in
blue. (a) Full molecule representation showing a large positively
charged loop (Arg35-Arg37A), believed to be implicated in the
binding of plasminogen activator inhibitors, in the foreground of
the picture. (b) Close-up of the active-site cleft, schematically
illustrating the S1, S2 and S3 binding pockets.
two-chain to single-chain molecules). This antagonism
cannot fully account for the high zymogenicity of
sc-u-PA, where substitutions occur in the corresponding
triad Ala32-Tyr40-Asp194.
The inhibitor complex
The inhibitor Glu-Gly-Arg chloromethyl ketone
(EGRcmk) is completely defined in the electron density
(Fig. 7). This density is consistent with the formation of a
tetrahedral hemiketal structure, that is, the carbonyl group
of the C-terminal Arg3I is covalently linked to Ser195 OGy
and, via the methyl group, to the imidazole ring nitrogen
(Ne2) of His57. The observed, irreversibly inhibited, sta-
ble tetrahedral state mimics a reaction transition state [34].
Figure 5 shows a surface representation of LMW u-PA
produced by the program GRASP [35], clearly showing
this negatively charged S1 binding pocket, which pro-
vides an ideal complementary binding environment for
Fig. 6. Substitution mutations performed by Davidow et al. [29]
and by Adams et al. [281. Davidow et al. mutations are modelled
into the LMW u-PA structure and are shown in a green ball-and-
stick representation labelled with the mutation (single-letter code
for amino acids). The relative activity of the mutant (as a percent-
age of the wild type) is shown in parentheses. All mutations can be
accommodated in the structure, the functional consequences of
the mutations being imposed by their position in the fold. G19R
and T1581 appear to disrupt normal activation; S45N, P28L and
G140D occur in the interface between the two subdomains.
A184T and T1881 are positioned around the S1 binding pocket;
G193R blocks access to the active-site cleft and C111Y com-
pletely disrupts the additional disulphide loop found in only a
small subset of trypsin-like serine proteases. The charged loop,
Arg35-Arg36-His37-Arg37A, which was studied by alanine scan-
ning mutagenesis [28] and is believed to be implicated in binding
of the plasminogen activator inhibitor, is highlighted in blue. (Fig-
ure produced using MOLSCRIPT [52] and RASTER 3D [53].)
the positively charged Arg3I. The side chain of Arg3I
extends into the S1 substrate pocket and makes a charge
interaction with Asp189 at the base of the pocket. Addi-
tional hydrogen bonds can be formed between the
guanido group of Arg3I and Serl90 Oy and between the
same guanido group and the main-chain carbonyl oxy-
gen of Gly218. Two main-chain hydrogen bonds
between inhibitor and protein are made (N3I to 0214,
and O1I to N216), forming a short, twisted, antiparallel
3-ladder. In addition, the N terminus of the inhibitor
can form a hydrogen bond to the carbonyl oxygens of
Ala98 and Gly216. The GlulI carboxylate of the
inhibitor forms a salt bridge to Arg217 and can form a
hydrogen bond to the nitrogen of Gly218 (Fig. 8).
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Fig. 7. 2Fo-Fc omit map of the inhibitor region in subunit 1: all
atoms of the inhibitor were excluded in the phasing model (con-
toured at la).
Comparison of the structure of the LMW
u-PA/EGR-cmk inhibitor complex with that of
D-Phe-Pro-Arg chloromethyl ketone complexed with
thrombin [34] shows that both the arginine residue and
the peptide backbone of the two inhibitors adopt essen-
tially the same conformation (Fig. 9). The S1 specificity
pocket is sterically similar to those of trypsin and throm-
bin and, moreover, the residues lining the S1 pocket are
identical to those of trypsin. The rms deviations for 17
Cots lining the pocket are 0.47 A and 0.42 A, for super-
position on bovine trypsin [36] and thrombin [19],
respectively. This is in contrast to the serine proteases that
are not specific for arginine or lysine, (x-chymotrypsin
[23] and elastase, [37], which have rms deviations of
0.97 A and 0.69 A respectively.
The specificity of serine proteases has been shown to be
mediated by sites beyond the S1-binding pocket, also
[38]. The sequences of known u-PA substrates demon-
strate that small hydrophobic residues are preferred at
the P2, P1' and P2' positions (Table 2). The EGRcmk
inhibitor, like plasminogen and u-PAR, contains a
glycine at the P2 position which can pack against the
imidazole ring of His99 in the S2 pocket. The loop
containing this histidine has a two-residue insertion
(VR3) when compared with thrombin and trypsin,
which significantly alters the local conformation, allow-
ing it to extend into the peptide-binding cleft. Residues
Leu97B and Ala98 form a hydrophobic lining, reducing
the accessibility of the active site. Residues at the P3
position and beyond are in a more exposed environ-
ment and thus a wider range of residues may be accom-
modated. The principal substrate, plasminogen,
contains a proline in the P3 position which probably
packs against the hydrophobic face presented by
Leu97B and Ala98 in the S3 pocket, providing addi-
tional binding energy. The binding pockets on the
C-terminal side of the cleavage site (S1', S2' etc.) can-
not be described with the same degree of detail because
of the lack of direct structural information on the posi-
tion of the substrate side chains. The preference for
hydrophobic residues in the P1' position suggests, how-
ever, that this residue packs in a solvent-inaccessible
manner, probably against the side chain of Val41 at the
S1' pocket. This S1' pocket, unlike that of thrombin, is
not restricted by an insertion and could accommodate
larger residues. Residues at the P2' position are known
to pack against the side chain of residue 151 [39]. In
u-PA, as in trypsin, this residue is a tyrosine, which lim-
its the size of the S2' pocket and thus those residues that
can occupy it.
Higher resolution structures of trypsin-like proteases
contain a number of structurally conserved solvent fea-
tures that are implicated in substrate binding. In these
structures, a water molecule is observed within the S1
specificity pocket at a suitable position for accepting a
hydrogen bond from the P1 residue. A network of sol-
vent molecules in a cavity behind Asp189 provides a pos-
sible route, through the back of the pocket, for the
expulsion of solvent upon binding of the P1 side chain
(Arg3I in this structure) [34]. Solvent molecules have not
been modelled in the LMW u-PA structure; however, a
water molecule could be accommodated within the S1
pocket in the manner discussed above, and a
Fig. 8. Stereo diagram illustrating inhibitor
binding interaction. Hydrogen bonds are
shown as dashed lines, the inhibitor is rep-
resented by an orange chain and labelled
in green. Regions around the inhibitor are
shown in standard atom colouring. (Figure
produced using MOLSCRIPT [52] and
RASTER3D [531)
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The structure of the u-PA protease domain is the first
from among the three enzymes of the fibrinolytic system
(u-PA, t-PA and plasmin) and, therefore, the LMW u-PA
structure will allow improved homology models of t-PA,
its close homologue, to be built. Two regions of u-PA
and t-PA are likely to be responsible for their different
specificities. In t-PA, the six-residue insertion after
Thr188 (Fig. 3) is of particular interest as it occurs before
Asp189, which is responsible for arginine binding. Fur-
thermore, a two-residue insertion in LMW u-PA relative
to t-PA and chymotrypsin (Thr97A-Ala98) is likely to
restrict access in the LMW u-PA-binding cleft. Know-
ledge of the u-PA protease domain structure may now
facilitate the structure-based design of active-site
inhibitors for potential clinical use as anti-metastatic
drugs. Several known u-PA inhibitors, which are selec-
tive for u-PA over t-PA and plasmin [40,41], may serve as
starting compounds for inhibitor design.
Fig. 9. Superposition of thrombin D-Phe-Pro-Arg chloromethyl
ketone inhibitor [19] and LMW u-PA EGRcmk based on super-
position of a-thrombin and LMW u-PA coordinates. The throm-
bin peptide is shown in red and the LMW u-PA peptide in violet.
(Figure produced using MOLSCRIPT [52] and RASTER 3D 53].)
solvent-accessible pocket is seen behind Aspl89. Thus, a
higher resolution LMW u-PA structure, including a
model for the ordered solvent structure, can be expected
to contain these conserved solvent features.
Conclusions
The structure presented completes the three module
u-PA 'mosaic' as experimentally derived models now
exist for each of its three component domains: the EGF-
like, kringle and protease domains. As NMR studies on
the dynamics of full-length u-PA have shown consider-
able interdomain freedom of motion and the structures
of all three of these domains have been solved, a compre-
hensive structural model now exists for u-PA. u-PA is
therefore an example for which the study of the isolated
domains of a flexible multidomain protein, combining
NMR and crystallographic techniques, has been success-
ful, whereas extensive studies on the complete enzyme
have proved fruitless.
Biological implications
Urokinase-type plasminogen activator (u-PA) is a
three-domain proteolytic enzyme possessing lim-
ited specificity, which catalyzes the conversion of
the inactive zymogen plasminogen to the active
protease plasmin. This event initiates plasmin-
mediated proteolysis of extracellular matrix pro-
teins, and the activation of other matrix-degrading
enzymes. Binding of the N-terminal domain of
u-PA to its receptor localizes proteolysis to cell sur-
faces while maintaining both its activity and its
characteristic inhibition. u-PA-initiated proteolysis
is believed to play a role in physiological processes
such as macrophage invasion, angiogenesis, wound
healing and ovulation and also in pathological
processes such as neoplasia and metastasis. Thus,
the specific inhibition of u-PA activity is a goal
with potential for use as an anti-metastatic therapy.
The crystal structure of the C-terminal domain of
u-PA, termed low molecular weight urokinase
(LMW u-PA), which contains the catalytic triad
His57, AsplO2 and Ser195, is shown to exhibit the
characteristic fold of other trypsin-like serine pro-
teases. This accounts for its activity, its specificity
for peptide bonds C-terminal to basic residues
and its activation mechanism. Substrate specificity
is mediated by the geometry of the active-site
cleft and particularly by the residues that line the
cleft. An understanding of u-PA specificity is
enhanced by the presence of the tripeptide
inhibitor, Glu-Gly-Arg chloromethyl ketone, in
the structure. The inhibitor binds covalently to the
enzyme in a manner which mimics a transition
state. The structure of the complex provides the
basis for future knowledge-based design of specific
u-PA inhibitors.
As solution structures exist for the N-terminal
growth factor domain and central kringle domain,
Table 2. Sequences around the scissile bond (arrow) of sub-
strates known to be cleaved by human tc-u-PA [54-57].
P4 P3 P2 P1 1 PI' P2' P3' P4'
Plasminogen (activation) C P G R V V G G
u-PA receptor (predicted) N S G R A V T Y
Plasminogen activator inhibitor-i V S A R M A P E
Plasminogen activator inhibitor-2 M T G R T G H G
Fibronectin T D V R IA A Y Y
Hepatocyte growth factor K Q L R IV V N G
Plasminogen (N terminus) I I I R IM R D V
Specificity for arginine at the P1 position is apparent, as is a
preference for small hydrophobic residues at P2, PI' and P2'.
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the structure presented here completes the model
of the full-length enzyme. Recently, the structures
of several serine proteases involved in the blood
coagulation and complement cascades have been
solved (thrombin, Factor X and Factor D). The
LMW u-PA structure is the first protease from the
fibrinolytic system and as such will help to
improve the molecular models of its close homo-
logues, tissue-type plasminogen activator and
plasmin. LMW u-PA differs from other serine
protease structures within several surface loop
regions. The largest difference is the incorpora-
tion of a four-residue insertion following residue
110 (Lys-Glu-Gly-Arg), which forms an extended
loop, stabilized by an additional disulphide bridge




The protein was derived from human u-PA expressed in E. coli
[42], and lacks the N-linked glycosylation at Asn302 present in
native u-PA. Recombinant low molecular weight urokinase-
type plasminogen activator (LMW u-PA, equivalent to
residues 135-411 of full-length u-PA) cleaved at the activation
site (Lysl58-Ile159) was purified by affinity chromatography
from the products of the digestion of recombinant human
sc-u-PA (saruplase) with plasmin. Saruplase (20 mg ml-1) was
mixed with plasmin (0.2 U ml-') at pH 8.4. After standing for
18 h at room temperature, the mixture was applied to a col-
umn (1.6x10 cm) of benzamidine-Sepharose equilibrated
with 50 mM Tris-HCl at pH 8.4. All fragments other than
amidolytically active LMW u-PA were washed from the col-
umn with the equilibration buffer before eluting the LMW
u-PA with 20 mM citrate buffer at pH 3.0.
LMW u-PA was inactivated by mixing a solution of LMW
u-PA (200 mg in 30 ml 50 mM phosphate buffer, pH 7.5)
with 10 mg Glu-Gly-Arg chloromethyl ketone (EGRcmk)
(Calbiochem) dissolved in 2 ml methanol. After 1 h of reaction
time at room temperature, the mixture was passed over a col-
umn of benzamidine-Sepharose which had been equilibrated
in 50 mM phosphate buffer, pH 7.5, and was then dialyzed
extensively against 1 mM HC1. Minor impurities were
removed by cation-exchange chromatography using a gradient
of NaCl (starting buffer 10 mS cm- 1, limiting buffer
45 mS c - l) in 25 mM citrate buffer, pH 4.0, to desorb the
inactive LMW u-PA from a column of Chelating-Sepharose
6B. The protein sample was further purified from small mole-
cule impurities and salts by 5 cycles of centrifugation at 4°C
using Centricon-3 concentration cells (Amicon).
Initial crystallization trials were conducted with the screening
method of Jancarik and Kim [43] (screen obtained from
Hampton Research, Riverside, CA). The hanging drop
vapour diffusion method was employed with 4 l drops of
equal volumes of protein and precipitant equilibrated against
a 700 ml reservoir. Small crystals were obtained within 24 h
in a drop suspended above a solution containing 15% PEG
8000 and 0.2 M Li2SO 4. Reduction of the PEG 8000 con-
centration by 1-2% produced medium-sized crystals
(0.25X 0.25X0.15mm3 ) which were suitable for X-ray
diffraction data collection.
Data collection and processing
Data were collected in-house at 20°C on an 18 cm diameter
Mar Research imaging plate system (j Hendrix and A Lentifer)
mounted on a Rigaku RU200 rotating anode CuK, X-ray
source (=1.54 A) with a planar graphite monochromator. An
initial 20 frames of data (each 0.5° oscillations exposed for
20 min), processed with the program XDS [44], showed the
crystals to belong to the space roup R3 with unit cell dimen-
sions a=b=176.7 A, c=54.4 A, ct=3=90 °, y=12 0°. Further
data were then collected to 3.1 A resolution with an oscilla-
tion range of 2.5 ° and an average exposure time of 45 min.
Higher resolution data were collected at 15°C with synchro-
tron radiation (=0.97 A) to a minimum Bragg spacing of
2.5 A at station BL6A2 of the Photon Factory (Japan). Weis-
senburg geometry was utilized in conjunction with a Fuji
BASIII phosphor imaging plate system. A typical exposure
time was 105 s with an oscillation range of 3.5 ° and a coupling
constant of 1.5° mm- 1. Resulting data were analyzed using the
program DENZO [45]. The final R-merge on all data to
2.5 A was 11.1%, the data being 60% complete to 2.5 A (on
observations >3r) (Table 1).
Molecular replacement
Initial phases for the data were provided by the generalized
molecular replacement strategy available in X-PLOR [46] using
the high-resolution structure of bovine et-chymotrypsin [23]
(Brookhaven Protein databank code, 4CHA) as a search model.
The solvent content, estimated as -60%, coupled with a self-
rotation function analysis, suggested that the crystal contained
two molecules in the asymmetric unit, related by a pseudo-
twofold axis. Peaks produced from the cross-rotation function,
using data between 8.0 A and 4.0 A resolution with a Patterson
radius of integration between 5 A and 20 A, were submitted to
a round of Patterson correlation refinement [47]. The two best
solutions, which are separated by 177 ° (in agreement with the
self-rotation function), were submitted to the X-PLOR transla-
tion search, which was performed as a grid search over the x
and y dimensions of the unit cell. Searches with the unmodified
monomeric ot-chymotrypsin coordinates produced no signifi-
cant peaks. Replication of the above procedure, but omitting all
those atoms outside a 15 A radius from the centre of mass of
the search model (corresponding to 60% of the ot-chymotrypsin
structure left in the search), produced clear peaks in the transla-
tion search for the two putative rotation solutions. The first,
with an 18.3% correlation coefficient 9.1tr above the mean and
5.9cr above the next highest peak, and the second, slightly less
significant, with a 13.0% correlation coefficient, 5.6cr above the
mean and 4.7cr above the next highest solution.
As the origin in z is not defined in space group R3, this was
fixed arbitrarily for the first molecule whilst a grid search in the
z direction was performed to position the second molecule rel-
ative to the first. The grid search produced a solution with a
correlation coefficient of 25.8%, which is 4.0 above the
mean, as opposed to 0.7cr for the next highest solution. The
final correlation coefficient, after rigid-body refinement of the
two molecules (using all atoms from the ot-chymotrypsin
model), was 26.2%, with an R-factor of 45.5% on all data
between 8.0 A and 4.0 A.
Model building and refinement
To reduce model bias three separate models were constructed
from three different serine proteases: bovine a-chymotrypsin,
bovine trypsin and porcine elastase (PDB codes 4CHA [23],
2PTN [36] and 3EST [37], respectively). For each, the
690 Structure 1995, Vol 3 No 7
appropriate molecule was rigid body fitted onto the a-chy-
motrypsin model solutions described above. The side chains of
LMW u-PA were added to each model in allowed conforma-
tions, using the program MUTATE (R Esnouf, unpublished
program), according to sequence alignments. The models
were then subjected to rounds of positional refinement using
all data from 8.0 A to 3.0 A and stereochemical parameters
derived from Engh and Huber [48]. At this initial stage, strict
non-crystallographic constraints were imposed in the refine-
ment. This was followed by simulated annealing refinement,
again within X-PLOR, cooling the model from 3500 K to
300 K in 50 K increments and separated by 0.5 fs of dynamics.
The final R-factors for the three models after individual
B-factor refinement were 30.0%, 29.7% and 28.3%, respec-
tively, with an rms deviation from bond length ideality of
0.011 A for each model. Electron-density maps calculated for
the three models were averaged with the program GAP M
Grimes and DI Stuart, unpublished program). This process
consisted of a superposition of the three maps followed by an
averaging of the electron density for the two molecules related
by non-crystallographic symmetry (ncs). At this stage, density
for the inhibitor was clearly visible as was that for the addi-
tional disulphide bridge which is present in u-PA but absent in
the models used for molecular replacement.
A composite model was built using information from the
three models by reference to the averaged map and insertions
were included where density permitted the tracing of the
chain. The model was then subjected to further rounds of
ncs-constrained refinement during which the R-factor
dropped to 27.2%. Molecular modelling and map interpreta-
tion stages were carried out using the programs FRODO [49]
and O [50], as implemented on an ESV10 workstation. All
measurements from 20.0 A to 3.0 A resolution were
included in the refinement and the X-PLOR (version 3.1)
bulk solvent correction applied. The R-factor for the model
fell to 25.5%. The inhibitor was then included in the model
at the active site and all data from 20.0 A to 2.5 A incorpo-
rated in the refinement. The two molecules in the dimer
were subjected to repeated cycles of ncs-restrained refine-
ment interspersed with manual rebuilding steps. The non-
crystallographic restraints were gradually removed from all
regions of the protein involved in crystal contacts; those
atoms comprising the core of the molecule were restrained
throughout the refinement. The R-factor of the final model
is 22.4% (20.4% on >3cr data) with an rms deviation in bond
length of 0.013 A. The program PROCHECK [51] indi-
cated that 68% of residues fall within the most favoured
regions of the Ramachandran plot and that no residues are in
the 'disallowed regions'.
The appropriateness of the strategy was judged by the free
R-factor values resulting from a number of parallel refinements
with various non-crystallographic restraints applied to the atomic
positions and temperature factors. The free R-factor (calculated
on 10% of the total observations) was rather insensitive to the
positional restraints (with a shallow minimum of 33.4% for the
scheme described above); however, stringent restraints on
B-factors were clearly inappropriate, increasing the free R-factor
by 2%. The final refinement was performed against all the avail-
able X-ray data. In summary the scheme used seems reasonable,
especially as we are not implying functional consequences to the
slight differences observed between the two molecules. Indeed,
the relationship between the two molecules (the final structures
are related by a rotation of 1780 about an axis that nearly inter-
sects the crystallographic threefold axis) is such that the structural
environments of the two molecules are similar, but one mole-
cule is significantly better defined, as judged by B-factors (the
mean main-chain B-factor of the first molecule is 38 A2 com-
pared with 49 A2 for the second molecule). This is in line with
the free R-factor results described above.
Coordinates have been deposited with the Protein Data Bank.
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